Jaguar Health reports Q2 2026 results, targets MVID NDA submission in Q2 2027

Jaguar Health, Inc. reported second-quarter 2026 financial results on August 19, 2026, tied to progress in its rare-disease development program for crofelemer. The company said a presentation at ESPGHAN 2026 described additional results of evaluation of crofelemer as adjunctive oral therapy for pediatric intestinal failure, showing reduction of parenteral support normalized to body weight of up to 48% in a patient with the ultrarare microvillus inclusion disease (MVID).¹ Jaguar said it expects the clinical package for an NDA for MVID to be ready by the end of 2026, allowing submission of the NDA in the second quarter of 2027.¹

On the commercial side, Jaguar noted that effective January 12, 2026, it entered a U.S. commercial licensing agreement with Woodward Specialty, LLC, an affiliate of privately held Future Pak, LLC, making Future Pak the exclusive U.S. marketer for Mytesi and Canalevia-CA1.¹ The company said it satisfied closing conditions in August 2026 to receive a non-dilutive $2 million holdback payment from Future Pak.¹ Napo remains the manufacturer of crofelemer and Mytesi and supplies product to Future Pak at cost-plus terms.¹

On R&D spending, Jaguar said R&D expense increased by about $0.1 million, from $3.2 million in the quarter ended June 30, 2025 to $3.3 million in the quarter ended June 30, 2026, primarily due to progress developing crofelemer into a powder formulation via lyophilization.¹ That formulation, the company said, is the new product formulation used in the rare disease intestinal failure clinical trials and anticipated for regulatory approval and commercialization.¹

On overall results, Jaguar reported total revenue, net of $1,225,000 for the quarter, down from $2,979,000 in the same quarter of 2025, a decrease of 59%, and a net loss attributable to common stockholders of $12,690,000, compared with $10,407,000 a year earlier.¹